Additionally, miR-22, which targets the TET2 tumor suppressor gene and its overexpression both in plasma and in CD34+ progenitor cells, was associated with high-risk subtypes of MDS, and decreased OS [50,66]. The gene discussed is TET2; the disease is myelodysplastic syndrome.